For individuals on a weight loss journey, the availability of medications has expanded, with GLP-1 weight loss pills now being an option. Two such pills, Wegovy (semaglutide) and Foundayo (orforglipron), have recently become available, offering an alternative to injectable medications. To make an informed decision between these two options, it’s essential to understand their mechanisms, effectiveness, and differences in administration.
Understanding Wegovy and Foundayo
The Wegovy pill, manufactured by Novo Nordisk, is an FDA-approved oral semaglutide medication for adults with overweight or obesity. It works by mimicking the glucagon-like peptide 1 (GLP-1) protein in the body, reducing hunger and slowing down food transit in the gut. The medication is taken once daily in the morning on an empty stomach with up to four ounces of water, with a 30-minute waiting period before eating or taking other medications.
Foundayo, on the other hand, is a GLP-1 medication made by Lilly, with the active ingredient orforglipron. It also mimics GLP-1 but has a small molecule structure, allowing it to pass through the gut intact regardless of food intake. This distinction is significant, as it enables patients to take the medication without strict fasting protocols or timing restrictions.
Efficacy and Comparison
Both medications have undergone extensive clinical trials, with similar weight loss results. Adults taking the highest dose of Foundayo lost an average of 27 pounds or 12.4% of their body weight over 72 weeks, while those on Wegovy lost an average of 33 pounds or 14% of their body weight over 64 weeks. However, a comparison of the two medications is complicated, as the results are based on separate clinical trials rather than a head-to-head comparison.
A Novo Nordisk press release reported that people on the Wegovy pill had significantly greater weight loss than those on Foundayo, but this comparison has been met with skepticism due to the lack of a direct head-to-head trial. Lilly has emphasized that their clinical trial program provides strong confidence in Foundayo’s performance in the real world.
Administration and Convenience
A significant difference between the two medications lies in their administration. Wegovy requires a strict morning routine, with a 30-minute waiting period before eating or taking other medications. In contrast, Foundayo can be taken at any time of day without food or water restrictions, making it a more convenient option for individuals with varying schedules or those who struggle with adherence to complicated dosing rules.
Related: How does the Alpha GPC powder help you?
Patients should consult their healthcare provider to determine the best medication for their individual needs. Doctors recommend considering factors such as lifestyle, schedule, and personal preferences when choosing between Wegovy and Foundayo.
Side Effects and Considerations
Both medications have similar potential side effects, including burping, constipation, diarrhea, fatigue, gas, headache, heartburn, nausea, stomach pain, and vomiting. Foundayo may also cause hair loss, indigestion, and swollen belly, while Wegovy may cause dizziness, feeling bloated, low blood sugar in people with type 2 diabetes, runny nose or sore throat, stomach flu, and upset stomach.
Ultimately, the choice between Wegovy and Foundayo depends on individual circumstances and priorities. Patients should have an open and honest conversation with their healthcare provider to determine the best course of treatment for their specific needs and goals.
In the context of weight loss medications, it’s essential to consider the broader implications of treatment. For instance, the effectiveness of these medications can be influenced by factors such as diet and exercise. Dr. Mir Ali suggests that patients still have to make the right choices, including eating the right foods. By taking a thorough approach to weight loss, individuals can maximize the benefits of these medications and achieve their health goals.
They must also consider the importance of a healthy lifestyle.
It is a single step.
